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Abstract
Cutaneous metastasis is a rare manifestation of advanced gastrointestinal (GI) cancers. Gastric
adenocarcinoma rarely presents with cutaneous metastasis, as cutaneous manifestations
occur in less than 1% of upper GI tract malignancies. Here, we present the case of a patient
with advanced gastric cardia adenocarcinoma with metastasis to the right occipital region of
the scalp. Following shave biopsy, the immunohistochemistry (IHC) and molecular profile of
the scalp lesion were analyzed, both of which confirmed metastasis and guided the treatment
approach. The lesion demonstrated programmed death ligand-1 (PD-L1), an immune
checkpoint protein, positivity by IHC, which led to the recommendation for treatment with
immunotherapy as per the National Comprehensive Cancer Network (NCCN) guidelines.
Clinicians should conduct dermatologic examinations in patients with a history of gastric
cancer or who are currently undergoing chemotherapy for gastric cancer in order to monitor for
disease progression or metastatic lesions. The aim of this report is to increase awareness of
scalp metastasis as an indicator of advanced internal visceral carcinoma for earlier diagnosis
and improved management of the condition.
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Introduction
Cutaneous metastasis is a rare manifestation of advanced gastrointestinal (GI) cancers. While
other tumor types such as lung, breast, and prostate cancers have well-documented cases of
metastasis to the skin and scalp, gastric adenocarcinomas rarely display cutaneous metastasis,
and it accounts for less than 1% of upper GI tract malignancies [1-3]. Patients with advanced
gastric cancer (defined as locally advanced or metastatic) have a dismal prognosis with a
median survival of 10-12 months [4]. While the liver, peritoneum, lung, and bone are the
common sites of metastases for gastric adenocarcinoma, here we describe a case where a
patient presented to the clinic with a growing scalp lesion that was subsequently biopsied
positive for metastatic gastric cancer.
Case Presentation
A 69-year old male with a past medical history of osteoarthritis and sarcoidosis presented to
the GI oncology clinic after a referral from gastroenterology. He complained of difficulty in
swallowing and unintended weight loss of 18 pounds over two months. He was obese with a
BMI of 32 with no history of gastroesophageal reflux disease (GERD) or no known history
1 1 2 3
4
 Open Access CaseReport  DOI: 10.7759/cureus.6781
How to cite this article
Menghani S V, Barbosa A, Sagerman P, et al. (January 27, 2020) Gastric Cardia Adenocarcinoma with
Metastasis to the Scalp: A Case Report. Cureus 12(1): e6781. DOI 10.7759/cureus.6781
of Helicobacter pylori (H. pylori) infection. His family history was positive for kidney cancer in
his father and stomach cancer in a maternal aunt. Diagnostic and staging evaluation with
endoscopic ultrasound (EUS), endoscopic biopsy, and PET/CT scan confirmed a Siewert type III
GEJ, cT3N0Mx, moderately differentiated adenocarcinoma. H. pylori immunohistochemical (
IHC) testing was negative. Upon multidisciplinary review with medical oncology, surgical
oncology, radiation oncology, and gastroenterology, the patient was offered perioperative
chemotherapy as standard of care (SOC) per NCCN guidelines [5,6]. However, the patient
reported that he had “connections” for “better treatment options” through non-disclosed
clinics outside of the US and was lost to follow-up.
Approximately 20 months post-initial diagnosis, the patient returned to the clinic reporting
that he had received a variety of non-SOC “curative treatments” in Mexico and China. He
noted that he had a scalp lesion that continued to grow and was bothersome, which he
attributed to bedsore. Upon dermatologic exam, a friable plaque with a yellow scale and crusts
was located in the right occipital region of the scalp. The scalp overall was erythematous and
tender to palpation. Dermatopathology review of the biopsied scalp lesion showed well-formed
glandular structures present through the dermal portion of the biopsy with focal lymphatic
invasion (Figure 1). The lesion was positive for expression of cytokeratin 7, cytokeratin 20
(Figure 2), and carcinoembryonic antigen (CEA) via IHC (Figure 3). Stains for caudal type
homeobox 2 (CDX2) and special AT-rich sequence-binding protein 2 (SATB2) were not done.
The lesion was negative for expression of P63, thyroid transcription factor 1 (TTF1), and
prostate-specific antigen (PSA). The final pathologic report concluded that this was metastatic
adenocarcinoma consistent with his history of gastric cancer. This prompted a restaging of
PET/CT, which showed diffuse fluorodeoxyglucose (FDG)-avid metastatic disease including
liver, skeleton, and occipital lesions (Figure 4). The biopsy specimen of the scalp was sent for
CARIS Molecular Intelligence (Caris Life Sciences, Inc., Dallas, TX) profiling, which revealed the
lesion to be positive for programmed death ligand-1 (PD-L1) upregulation by IHC.
FIGURE 1: Right occipital scalp lesion dermatopathology
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H&E stain showing well-formed glandular structures present with focal lymphatic invasion; red
arrows indicate representative focal lymphatic invasion and glandular structures (original
magnification x200)
H&E: hematoxylin and eosin
FIGURE 2: Right occipital scalp lesion immunohistochemistry
showing positivity for cytokeratin 20 (original magnification
x100)
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FIGURE 3: Right occipital scalp lesion immunohistochemistry
showing positivity for CEA (original magnification x200)
CEA: carcinoembryonic antigen
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FIGURE 4: Restaging PET/CT image of the patient
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Restaging image obtained with evidence of right occipital metastasis; sagittal view presented with
red arrow indicating occipital lesion
PET; positron emission tomography; CT: computed tomography
The molecular information derived from the scalp lesion helped guide management as
immunotherapy has been FDA-approved for the treatment of PD-L1-positive metastatic gastric
and esophageal cancers in the subsequent line setting. Expression of PD-L1 has been shown to
be a prognostic indicator for immunotherapy in metastatic gastric adenocarcinoma [7].
Objective responses to immune checkpoint inhibitor therapy have been shown, which led to
the FDA approval of pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, as a ≥3rd-line
treatment option for PD-L1 expressing with a combined positive score (CPS) of ≥1 in metastatic
gastric cancer [8-10]. As our patient had progressed on multiple chemotherapy regimens and
since his molecular pathology demonstrated PD-L1 positivity with CPS 1, he was started on
pembrolizumab monotherapy. Unfortunately, due to extensive metastatic disease, the patient
passed away several weeks after the initiation of pembrolizumab.
Discussion
Gastric adenocarcinomas rarely display cutaneous metastasis, but case reports of this have
been reported over the years. Previously reported cases of cutaneous metastatic manifestations
of gastric adenocarcinoma have described symptoms reported 3-10 years after the primary
diagnosis [11]. Cutaneous metastases have been described as part of the natural history of
disease progression in individual patients [11]. A brief literature review of PubMed articles
indexed for MEDLINE yielded 10 relevant case reports with similarities to our patient, but with
noted differences. Several cases, including those discussed by Lifshitz et al., Woo et al., and Cho
et al., describe scalp or skin metastasis as a recurrence of gastric cancer [12-14]. The report by
Sakaki et al. from 1979 describes scalp and dural lesions in the right parietal region with gastric
adenocarcinoma found at autopsy [15]. Several case reports describe alopecia neoplastica as a
paraneoplastic sequela of gastric adenocarcinoma [16,17]. The case report and literature review
by Du et al. do not describe the IHC or molecular profile of the lesion, focusing instead on
radiology- and pathology-based evidence [18]. A further review of the relevant results showed
no results utilizing the IHC profile and molecular profiling of the metastatic lesion to guide the
treatment approach for both primary and metastatic lesions.
Overall, our patient had a relatively poor prognosis from his initial PET/CT. Patients with
advanced gastric cancer (defined as locally advanced or metastatic) have a median survival of
10-12 months [4]. The National Cancer Institute Surveillance, Epidemiology, and End Results
Program (SEER) database reports an overall 5-year survival rate from gastric cancer of 31.5%.
Patients with a distant disease (defined as having metastasized) have a 5-year relative survival
rate of 5.3%. In gastric cancer treatment, the use of immunotherapy has been a growing trend.
For patients enrolled in Phase 2 KEYNOTE-180 study with gastric adenocarcinoma that
progressed over two treatment regimens and with PD-L1-positive tumors, there was a 13.8%
objective response rate [8,9]. The main benefits of anti-PD-1 immunotherapeutic agents are the
manageable safety profile and promising antitumor activity in this setting [10]. For our patient,
cutaneous metastasis was a distinct sign of disease progression and the use of pembrolizumab
was palliative. As shown by the PET/CT image, there was evidence of diffuse FDG-avid
metastatic disease affecting the liver, skeleton, and occipital region. The liver and skeleton
are locations where the metastatic disease is commonly seen; however, the occipital lesion is
uncommon in these organs [3].
Conclusions
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We reported a case of a patient with cutaneous scalp metastasis from a primary gastric cardia
adenocarcinoma. Cutaneous metastasis is a rare but clinically accepted manifestation of
advanced internal visceral carcinoma such as gastric adenocarcinoma. The scalp lesion IHC
profile (cytokeratin 7, cytokeratin 20, and CEA positivity) and molecular profiling (PD-L1
positivity) were used to guide the treatment approach for both the primary and metastatic
lesions. We encourage the clinicians to perform a thorough dermatologic examination in
patients with a history of gastric cancer, especially in the setting of new dermatologic
symptoms/findings during treatment and/or surveillance. We also aim to increase awareness
regarding scalp metastasis as an indicator of advanced internal visceral carcinoma, which would
help in earlier diagnosis and improved management of patients.
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